Hemoglobin glutamer-250 (bovine) in South Africa: consensus usage guidelines from clinician experts who have treated patients

Transfusion

Volumn 56, Issue 10, 2016, Pages 2631-2636

  Mer, Mervyn ^a   Hodgson, Eric ^b   Wallis, Lee ^c   Jacobson, Barry ^d   Levien, Lewis ^e   Snyman, Jacques ^f   Sussman, Martin J ^g   James, Mike ^h   van Gelder, Antoine ^f   Allgaier, Rachel ^c   Jahr, Jonathan S ⁱ  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e Sunninghill Hospital   (South Africa)

^f UNIVERSITY OF PRETORIA   (South Africa)

^g MILPARK HOSPITAL   (South Africa)

^h UNIVERSITY OF CAPE TOWN   (South Africa)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYMERIZED HEMOGLOBIN; BLOOD SUBSTITUTE; HEMOGLOBIN; OXYGEN;

ANEMIA; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; METHEMOGLOBINEMIA; MICROCIRCULATION; NOTE; OXYGEN DISSOCIATION CURVE; OXYGEN TENSION; OXYGEN TISSUE LEVEL; OXYGEN TRANSPORT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOUTH AFRICA; ANIMAL; BOVINE; CONSENSUS; ERYTHROCYTE TRANSFUSION; METABOLISM; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PROCEDURES;

ANIMALS; BLOOD SUBSTITUTES; CATTLE; CONSENSUS; ERYTHROCYTE TRANSFUSION; HEMOGLOBINS; HUMANS; OXYGEN; PRACTICE GUIDELINES AS TOPIC; PRODUCT SURVEILLANCE, POSTMARKETING; SOUTH AFRICA;

EID: 84991688062     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13726     Document Type: Note

References (22)

1. Natanson C, Kern SJ, Lurie P, et al. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA 2008;299:2304–12.
2. Jahr JS, Mackenzie C, Pearce LB, et al. HBOC-201 as an alternative to blood transfusion: efficacy and safety evaluation in a multicenter phase III trial in elective orthopedic surgery. J Trauma 2008;64:1484–97.
3. Mackenzie CF, Moon-Massat PF, Shander A, et al. When blood is not an option: factors affecting survival after the use of a hemoglobin-based oxygen carrier in 54 patients with life-threatening anemia. Anesth Analg 2010;110:685–93.
4. Freilich D, Pearce LB, Pitman A, et al. HBOC-201 vasoactivity in a phase III clinical trial in orthopedic surgery subjects—extrapolation of potential risk for acute trauma trials. J Trauma 2009;66:365–76.
5. Mackenzie CF, Pitman AN, Hodgson RE, et al. Are hemoglobin-based oxygen carriers being withheld because of regulatory requirement for equivalence to packed red blood cells? Am J Ther 2015;22:e115–21.
6. Levien LJ. South Africa: clinical experience with Hemopure. ISBT Sci Ser 2006;167–73.
7. Van Hemelrijck J, Levien LJ, Veeckman L, et al. A safety and efficacy evaluation of hemoglobin-based oxygen carrier HBOC-201 in a randomized, multicenter red blood cell controlled trial in noncardiac surgery patients. Anesth Analg 2014;119:766–76.
8. McLean E, Cogswell M, Egli I, et al. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005. Public Health Nutr 2009;12:444–54.
9. Anbari KK, Garino JP, Mackenzie CF. Hemoglobin substitutes. Eur Spine J 2004;13:76–82.
10. Standl T, Freitag M, Burmeister MA, et al. Hemoglobin-based oxygen carrier HBOC-201 provides higher and faster increase in oxygen tension in skeletal muscle of anemic dogs than do stored red blood cells. J Vasc Surg 2003;37:859–65.
11. Hughes GS, Yancey EP, Albrecht R, et al. Hemoglobin-based oxygen carrier preserves submaximal exercise capacity in humans. Clin Pharmacol Ther 1995;58:434–43.
12. Mackenzie CF, Shander A. What to do if no blood is available but the patient is bleeding? South Afr J Anaesth Analg 2008;14:39–43.
13. Reid TJ. Hb-based oxygen carriers: are we there yet? Transfusion 2003;43:280–7.
14. Mullon J, Giacoppe G, Clagett C, et al. Transfusions of polymerized bovine hemoglobin in a patient with severe autoimmune hemolytic anemia. N Engl J Med 2000;342:1638–43.
15. Donahue LL, Shapira I, Shander A, et al. Management of acute anemia in a Jehovah's Witness patient with acute lymphoblastic leukemia with polymerized bovine hemoglobin-based oxygen carrier: a case report and review of literature. Transfusion 2010;50:1561–7.
16. Go AS, Yang J, Ackerson LM, et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation 2006;113:2713–23.
17. Kim HW, Tai J, Greenburg AG. Active myogenic tone: a requisite for hemoglobin mediated vascular contraction? Artif Cells Blood Substit Immobil Biotechnol 2004;32:339–51.
18. Tobias JD, Ramachandran V. Intraoperative diagnosis of unsuspected methemoglobinemia due to low pulse oximetry values. J Intensive Care Med 2009;24:273–7.
19. Dubé GP, Vranckx P, Greenburg AG. HBOC-201: the multi-purpose oxygen therapeutic. EuroIntervention 2008;4:161–5.
20. Mongan PD, Moon-Massat PF, Rentko V, et al. Regional blood flow after serial normovolemic exchange transfusion with HBOC-201 (Hemopure) in anesthetized swine. J Trauma 2009;67:51–60.
21. Potgieter HE, James MF. The use of Hemopure® at Groote Schuur hospital, Cape Town: 4 case studies. SAJAA 2009;15.
22. Weiskopf RB, Silverman TA. Balancing potential risks and benefits of hemoglobin-based oxygen carriers. Transfusion 2013;53:2327–33.